title: [Castration resistant prostate cancer 2015].
abstract: Prostate cancer is still the most common urological cancer of the elderly man. In some patients, a metastatic prostate cancer arises which may remain a stable disease for years with palliative antiandrogen therapy. On average, after 3-4 years, affected men develop a PSA rise and disease progression with the formation of a so-called castration-resistant disease. 5 years ago cytotoxic chemotherapy with docetaxel was the only life-prolonging treatment option in this situation. In the last 5 years, the results of randomised phase III studies have led to the approval of 5 new agents for the treatment of metastatic castration resistant prostate cancer (mCRPC). The results and approval status of the substances, Abiraterone, Enzalutamide, Cabazitaxel, Sipuleucel-T and radium-223 are described below. In addition, some aspects of sequential therapy and possible future molecular approaches are discussed.
authors: Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Hannover.
authors: A S
authors: AS
authors: Merseburger
authors: Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Hannover.
authors: A
authors: A
authors: Böker
authors: Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Hannover.
authors: M A
authors: MA
authors: Kuczyk
authors: Klinik für Urologie und Urologische Onkologie, Medizinische Hochschule Hannover, Hannover.
authors: C-A
authors: CA
authors: von Klot
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood; D064129:Prostatic Neoplasms, Castration-Resistant / Q000097:blood / Q000473:pathology / Q000628:therapy*; D011868:Radioisotopes / Q000627:therapeutic use; D011883:Radium / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D011868:Radioisotopes; D017430:Prostate-Specific Antigen; C581106:radium Ra 223 dichloride; D011883:Radium